Analyst Jason McCarthy from Maxim Group maintained a Buy rating on MetaVia (MTVA – Research Report) and keeping the price target at $6.00.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding MetaVia’s recent clinical trial data and future prospects. The company recently reported promising top-line results from its Phase 1 study of DA-1726, a dual oxyntomodulin analog targeting GLP1 receptors. These results showed a dose-dependent reduction in body weight without significant cardiovascular risks, which is a common concern in this drug class. This positive safety profile suggests that DA-1726 may have advantages over existing treatments, and MetaVia plans to explore additional dosing levels to potentially improve efficacy.
Furthermore, MetaVia’s stock experienced a sharp decline following earlier data announcements, which McCarthy believes was an overreaction that overlooked the comprehensive data. The ongoing study and the upcoming transition to Part 3, which will focus on obese patients who have discontinued other treatments due to tolerability issues, present further opportunities for MetaVia. Additionally, the company’s upcoming presentation at the EASL Congress on its MASH program highlights its broader pipeline potential, reinforcing McCarthy’s optimistic outlook and Buy rating.
In another report released on April 16, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.